Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

ABIOMED (ABMD) To Report Q3 Earnings: What's In The Offing?

Published 01/30/2020, 10:44 PM
Updated 07/09/2023, 06:31 AM
ABIOMED, Inc. (NASDAQ:ABMD) is scheduled to release third-quarter fiscal 2020 results on Feb 6, before market opens. We believe that despite the persistent foreign currency woes, solid Impella product line prospects are expected to reflect on the results.
ABIOMED delivered an earnings surprise of 10.8% in the last reported quarter, the trailing four-quarter earnings surprise being a positive 3.7%, on average.
Q3 Estimates Picture
The Zacks Consensus Estimate for ABIOMED’s third-quarter earnings per share is pegged at $1.09, indicating a year-over-year improvement of 12.4%.
Let’s see how things are shaping up prior to the earnings release.

ABIOMED, Inc. Price and EPS Surprise

ABIOMED, Inc. Price and EPS Surprise

ABIOMED, Inc. price-eps-surprise | ABIOMED, Inc. Quote

Impella Likely to Drive Q3 Results
ABIOMED’s flagship product line, Impella, has consistently boosted the company’s top line. Impella, a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart, is expected to have driven fiscal third-quarter earnings as well.
Notably, the treatment success rates of ABIOMED’s SmartAssist, Impella Connect, IQ Impella Quality Assurance Database and Impella 5.0 is expected to reflect in the quarterly results.
Apart from these, the recent post-approval studies for Impella 5.5 have received a nod from the FDA, which signifies increasing adoption of the device. Additionally, recent FDA approval of the Impella 5.5 with SmartAssist and plans to launch the same in the United States also buoy optimism. Moreover, Impella 2.5 and CP with SmartAssist are currently much in demand.
Notably, ABIOMED’s preliminary results project U.S. patient usage growth of 16% year over year and international growth of 24%. U.S. revenues are expected to have grown 8% year over year to $185.6 million. Internationally, revenues are estimated at $36.0 million, suggesting a 29% year-over-year rise on strength in Germany and Japan.
Thus, quarterly revenues are anticipated at $221.6 million, suggesting a 10% year-over-year rise but the metric is expected to lag the consensus mark.
Resultantly, the company slashed its fiscal 2020 revenue guidance.
Revenues are now expected within $846-$877 million, indicating an increase of 10-14% year over year. This compares to the earlier projected range of $885-$925 million, calling for a 15-20% rise year over year.
However, ABIOMED faces stiff competition in the global MedTech space and fluctuations in currency exchange rates.
Earnings Whispers
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. That is not the case here as you will see below.
Earnings ESP: ABIOMED has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: ABIOMED carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
DexCom (NASDAQ:DXCM) has an Earnings ESP of +17.07% and a Zacks Rank #2.
AmerisourceBergen (NYSE:ABC) has an Earnings ESP of +0.82% and a Zacks Rank #3.
HealthEquity (NASDAQ:HQY) has an Earnings ESP of +18.56% and a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.


ABIOMED, Inc. (ABMD): Free Stock Analysis Report

DexCom, Inc. (DXCM): Free Stock Analysis Report

AmerisourceBergen Corporation (ABC): Free Stock Analysis Report

HealthEquity, Inc. (HQY): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.